Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107477 | 0.92 | RAB9A (0.42) | RXFP1MAPTHSD11B1RAB9AKMT2A | |
| SCHEMBL3105220 | 0.92 | RAB9A (0.46) | RXFP1HPGDMAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL3109046 | 0.91 | KMT2A (0.51) | RXFP1HPGDMAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL3114886 | 0.89 | RAB9A (0.41) | RXFP1HPGDMAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL3110448 | 0.89 | PLK1 (0.42) | RXFP1HPGDMAPTHSD11B1RAB9A | |
| SCHEMBL3110919 | 0.88 | MAPK14 (0.45) | RXFP1HPGDHSD11B1KMT2ATTK | |
| SCHEMBL3107213 | 0.88 | CHRNA10 (0.42) | RXFP1HPGDMAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL3108824 | 0.86 | ATM (0.41) | RXFP1HPGDMAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL3117690 | 0.86 | MAPK14 (0.46) | RXFP1HPGDMAPTSMN1; SMN2KMT2A | |
| SCHEMBL3102917 | 0.86 | MAPK14 (0.40) | RXFP1MAPTHSD11B1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | RXFP1 77/4885HPGD 800/4885MAPT 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.